Published in final edited form as:

Neurosci Lett. 2015 March 4; 589: 19–24. doi:10.1016/j.neulet.2015.01.009.

Activation of Cannabinoid Receptor 1 Inhibits Increased Bladder Activity Induced by Nerve Growth Factor

Zun-Yi Wang^{1,*}, Peiqing Wang¹, and Dale E. Bjorling^{1,2,*}

¹Department of Surgical Sciences, University of Wisconsin, Madison, WI

²Department of Urology, University of Wisconsin, Madison, WI

Abstract

Nerve growth factor (NGF) is an important mediator of inflammatory pain, in part by sensitizing afferent nerve fibers, and expression of NGF is increased during bladder inflammation. We investigated whether intravesical instillation of the selective cannabinoid receptor 1 (CB1) agonist arachidonyl-2'-chloroethylamide (ACEA) affects NGF-induced increased bladder activity in female C57BL/6J wild-type (WT) mice. We also examined the effects of intravesical NGF in female fatty acid amide hydrolase knock-out (FAAH KO) mice. We found that CB1 and tyrosine kinase A (trkA, the high-affinity NGF receptor) were present in L6 dorsal root ganglion (DRG) afferent neurons and in bladders of both genotypes. Intravesical NGF increased bladder activity that was inhibited by intravesical ACEA in WT mice. The inhibitory effects of ACEA were reversed by the selective CB1 antagonist AM 251. Intravesical NGF failed to affect bladder activity in FAAH KO mice, and treatment with AM251, restored the stimulatory effects of NGF on the bladder in FAAH KO mice. These results indicate that activation of CB1 inhibits increased bladder activity induced by NGF.

Keywords

Nerve growth factor; fatty acid amide hydrolase; Cannabinoid receptor 1; tyrosine kinase A; Bladder; Mice

1. Introduction

Visceral pain can be extremely disabling and commonly occurs in the 7-8 million patients identified annually in the U.S. with painful bladder syndrome (PBS) [1, 2]. Causes of PBS remain unknown, and this disorder has proved singularly resistant to effective prevention or treatment [1-3]. Many tissues produce fatty acid ethanolamides, a family of compounds that includes endocannabinoids such as *N*-arachidonylethanolamine (AEA), also called

© 2015 Elsevier Ireland Ltd. All rights reserved.

*Corresponding Author Dr. Zunyi Wang wangz@svm.vetmed.wisc.edu or Dr. Dale Bjorling bjorling@svm.vetmed.wisc.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

The authors declare no conflict of interest.

anandamide that can exert potent analgesic and anti-inflammatory effects [4-6]. AEA is primarily degraded by fatty acid amide hydrolase (FAAH), and inhibition of FAAH is thought to exert analgesic effects by increasing tissue contents of AEA [5, 6]. Previous work in our laboratory suggests that pharmacological inhibition or genetic deletion of FAAH has the capacity to ameliorate pain associated with bladder inflammation [7, 8]. Recently, Aizawa et al. [9] reported that FAAH inhibition reduced bladder afferent nerve activity via activation of cannabinoid receptor 1 (CB1) and 2 (CB2). Other studies have also shown that activation of CB1 suppressed enhanced afferent nerve activity induced by mechanical stimulation [28] or by bladder inflammation [10]. However, fundamental mechanisms that modulate analgesic and anti-inflammatory effects of cannabinoids remain unclear.

Tissue injury and inflammation generate an array of chemical mediators, including nerve growth factor (NGF). Acute exposure to NGF has been shown to rapidly increase the activity of primary afferent neurons and their nerve fibers (sensitization) [11]. NGF has been shown to be an important mediator of inflammatory pain, in part by sensitizing afferent nerve fibers, and expression of NGF is increased during bladder inflammation [12-14]. Intravesical instillation of NGF into bladders of rodents enhanced bladder activity [15, 16] and produced visceral pain [17, 18] that was prevented by administration of either anti-NGF antiserum or by inhibitors of the NGF receptor *trkA* [17, 18]. Further, overexpression of NGF in urothelium [19], chronic infusion of NGF into detrusor [20], or repeated intraperitoneal injection of NGF [21], increased bladder activity in rodents. We recently demonstrated that activation of CB1 attenuates NGF-induced sensitization in cultured mouse DRG afferent neurons [22]. In the current study, we investigated whether treatment with a selective CB1 agonist arachidonyl-2'-chloroethylamide (ACEA) diminished NGF-induced increased bladder activity in female wild-type (WT) mice. We also examined the effects of intravesical NGF on bladder activity in female FAAH knock-out (KO) mice.

2. Methods

Animals

C57BL/6J WT mice were obtained from The Jackson Laboratory (Bar Harbor, ME). FAAH KO mice were back-crossed to a C57BL/6J background [5] and breeding pairs of FAAH KO mice were generously provided by Dr. Aron Lichtman (Virginia Commonwealth University). Female mice were used at 3-6 months of age and were age-matched among control and treatment groups. Experiments were conducted in accordance with National Institutes of Health Guidelines, and all protocols were reviewed and approved by the Animal Care and Use Committee of the University of Wisconsin.

Immunohistochemistry

Mice were euthanized with pentobarbital (100 mg/kg, ip) and perfused with saline through a cannula inserted into the left ventricle followed by 2 % paraformaldehyde in 0.1 M phosphate-buffered saline (PBS). Bladders and L6 DRGs that provide afferent innervation to the bladder were removed, post-fixed in the same fixative for 4 hours, and cryoprotected with 30 % sucrose in PBS at 4° C. Tissue sections were made with a cryostat at a thickness of 12 µm. Sections were blocked with 10 % normal goat serum for 1 hour, and then a

polyclonal anti-CB1 (1:200, diluted in PBS containing 0.1 % BSA, 0.3 % Triton-X 100, Cayman Chemical, Ann Arbor, MI) [10, 39] or anti-trkA antibody (1: 500, Abcam, Cambridge, MA) [22] was applied. Negative staining controls were prepared using normal rabbit IgG instead of the specific antibody. Slides were kept in a humid chamber for 48 hours at 4° C, and staining was revealed using secondary goat anti-rabbit IgG conjugated with Alexa Fluor® (1:1000, Life Technologies, Grand Island, NY). Slides were coverslipped with an anti-fading solution (Vector Labs, Burlingame, CA). Staining was examined with a Nikon E600 microscope, and photoimages from stained and negative control were acquired. Staining intensities of neurons from negative controls were measured as a grey level on a 0-255 scale, and the averaged value of negative controls was used as the threshold to differentiate labeled from negative neurons. Four to six sections stained with CB1 or trkA antibody from each animal were examined. The number of positively labeled neurons was counted and normalized to the total number of neurons examined as described previously [22, 23].

Effects of NGF on bladder activity

Mice were anesthetized with urethane (1.2 g/kg, ip). Thirty minutes later, a catheter (PE 10) was placed through urethra, and bladder was emptied by light abdominal compression. Ten minutes later, saline was infused at a rate of 0.8 ml/hour into the bladder by a syringe pump (Harvard Apparatus, Holliston, MA), and bladder pressure was monitored continuously with a pressure transducer (BD Biosciences, San Jose, CA). The bladder pressure was recorded using WinDaq software (Dataq Instruments, Akron, OH) with a PC computer. The amount (µl) of saline needed to induce the maximal micturition pressure was measured (baseline). Bladders were then emptied, and either NGF (2 µg in 100 µl saline containing 10 % DMSO, Promega, Madison, WI) or vehicle (10 % DMSO in saline) was instilled into bladder and left in place for 1 hour [17]. The bladder was then emptied by light abdominal compression. Thirty minutes after NGF or vehicle was removed from the bladder, saline was infused into the bladder, and the amount (µl) of saline required to induce maximal micturition pressure was determined. This value was normalized as % of the baseline value in each individual animal, and the reduction in this value is indicative of increased bladder activity [15].

Activation of CB1 on NGF-induced responses

In separate experiments, the CB1 agonist ACEA (100 µM in 100 µl saline containing 10 % DMSO, Tocris, Bristol, UK) or CB1 antagonist AM251 (1 mM, Tocris) + ACEA (100 µM) in 100 µl saline containing 10 % DMSO was instilled into the bladder and left in place for 30 minutes prior to treatment with NGF in WT mice. The CB1 antagonist AM251 (1 mM) was instilled into bladders of FAAH KO mice 30 minutes prior to treatment with NGF. The dosage of ACEA was chosen based on previous publications relevant to the present study [10, 40]. The affinity of ACEA and AM251 to CB1 receptors is 1.4 and 7.5 nM, respectively (Tocris). Therefore, AM 251 and ACEA were used at 1:10 ratio to ensure blockade of CB1 receptors by AM251 in the presence of ACEA. Both ACEA and AM251 were dissolved in DMSO at 10 mM as stock solution stored at -20° C, and working solutions were prepared freshly prior to each experiment.

Statistical analysis

Data are presented as arithmetic means $\pm$ SEM. Data from multiple groups were analyzed using one-way ANOVA followed by post hoc Tukey's multiple comparison test (GraphPad Prism, San Diego, CA). Unpaired Student's t-tests were used as appropriate to compare data between 2 groups. p values < 0.05 were considered significant.

3. Results

Specific antibodies revealed positive immunostaining for CB1 and trkA in L6 DRGs from both genotypes (Figure 1). Neurons were considered labeled with the specific antibody when the fluorescent intensity was distinctively higher than controls. Positive staining was primarily observed in small- to medium-sized afferent neurons and nerve fibers in DRG. The number of CB1 positive neurons was $63.8 \pm 2.3\%$ and $60.4 \pm 4.8\%$ in L6 DRGs of WT and KO mice, respectively ($n = 4$, $p > 0.05$). The number of trkA positive neurons was $50.7 \pm 3.5\%$ and $51.8 \pm 5.4\%$ in L6 DRGs of WT and KO mice, respectively ($n = 4$, $p > 0.05$). Positive staining for CB1 and trkA was also observed in urothelium and nerve fibers in bladders of all mice examined (Figure 1). Replacing specific antibodies with normal rabbit IgG resulted in complete lack of specific staining (not shown).

Infusion of saline into bladders induced micturition contraction in mice (Fig. 2A). In vehicle-treated WT mice, the amount of saline needed to induce the maximal micturition pressure was similar to baseline value (Figure 2B). Intravesical NGF reduced this value significantly ($p < 0.05$ vs vehicle-treated), and treatment with ACEA prevented this effect of NGF ($p > 0.05$ vs vehicle-treated, Figure 2B). The inhibitory effects of ACEA were reversed by the selective CB1 antagonist AM251 ($p < 0.01$ vs ACEA-treated; Figure 2B). Treatment with NGF, ACEA+NGF, or AM251+ACEA+NGF did not affect the maximal micturition pressure (Figure 2C).

The baseline volume of saline needed to induce the maximal micturition pressure was greater in FAAH KO than in WT mice (254.5 ± 19.1 vs 147.8 ± 6.3 μ l, $n = 20-29$, $p < 0.01$). NGF did not alter the amount of saline needed to induce the maximal micturition pressure ($p > 0.05$) in FAAH KO mice, but treatment with the selective CB1 antagonist AM251 prior to NGF significantly reduced this value ($p < 0.05$ vs NGF-treated; Figure 3A). Treatment with NGF or AM251 +NGF did not affect the maximal micturition pressure (Figure 3B).

4. Discussion

Several reports indicate that CB1 is present in small- and medium-sized nociceptive neurons [9, 23-25]. It has been shown previously that these neurons also frequently express trkA [22, 26-29]. Walczak and Cervero [10] demonstrated that CB1 is present in afferent nerve fibers in mouse bladders. Furthermore, CB1 and trkA have also been detected in urothelium of bladders from various species, including human beings [10, 30-32, 34-38]. We provide additional evidence that CB1 and trkA are consistently observed in small- to medium-sized adult mouse afferent neurons as well as in urothelium and nerve fibers. These observations collectively suggest the potential for functional interactions between CB1 and trkA in regulating bladder activity and nociception.

Farquhar-Smith and Rice reported that intraplantar administration of NGF to the hind paw of rats induced thermal hyperalgesia, and treatment with AEA inhibited the effects of NGF via activation of CB1 [33]. These authors also demonstrated that intravesical installation of NGF in rats increases bladder activity, and systemic treatment with AEA attenuated effects of NGF via activating both CB1 and CB2 [15]. These studies clearly indicate that cannabinoids are capable of modulating the effects of NGF. However, systemically administered cannabinoids likely act at multiple sites, including the CNS, to exert inhibitory effect on NGF-induced responses. In the present study, we found that intravesical treatment with NGF increased bladder activity in mice that was blocked by local (intravesical) activation of CB1 in bladders. In FAAH KO mice, AEA content is increased in various tissues, including bladders [5, 8], and NGF failed to affect bladder activity in these mice. Interestingly, local treatment with a specific CB1 antagonist restored the stimulatory effects of NGF on bladder activity, suggesting that inhibition of NGF-induced responses in FAAH KO mice was, at least in part, mediated by CB1 receptors within the bladder wall. Collectively, these results demonstrate that local activation of CB1 is capable of inhibiting the effects of NGF in the bladder. In a previous study, we demonstrated that treatment with ACEA prevented NGF-induced sensitization of cultured afferent neurons by inhibiting the NGF-induced phosphorylation of AKT pathway [22]. Further investigation is required to determine whether the inhibitory effects of CB1 activation on NGF-induced increased bladder activity are mediated by AKT and other cellular signaling pathways related to NGF activity.

Similar to previous reports [30-32, 34, 35], we observed that both trkA and CB1 are present in urothelium. Increasing evidence suggests that the urothelial cells have the capacity to secrete a variety of signaling molecules such as NGF, nitric oxide, and cytokines in response to various stimuli, thereby playing an important role in physiological and pathophysiological processes in the bladder [36-38]. Conceivably, chemical mediators derived from urothelial cells, such as NGF, influence bladder function and pain sensation during bladder inflammation. However, little is known about functional consequences following activation of trkA and CB1 in urothelial cells. Additional studies are needed to investigate their functional role, as well as potential interactions between these two proteins, in urothelial cells in future.

In conclusion, intravesical NGF increased bladder activity as reflected by reducing the amount of infused saline needed to induce the maximal micturition pressure in WT mice. This effect of NGF was prevented by local treatment with a selective CB1 agonist in the bladder. Intravesical NGF failed to affect bladder activity in FAAH KO mice, and intravesical instillation of a CB1 antagonist restored the stimulatory effects of NGF in FAAH KO mice. These results indicate that local activation of CB1 inhibits increased bladder activity induced by NGF.

Acknowledgements

This study was supported by NIH R01 DK 066349 (DEB).

Funding: NIH DK R01 088806 (DEB)

References

- van de Merwe JP, Nordling J, Bouchelouche P, Bouchelouche K, Cervigni M, Daha LK, Elneil S, Fall M, Hohlbrugger G, Irwin P, Mortensen S, van Ophoven A, Osborne JL, Peeker R, Richter B, Riedl C, Sairanen J, Tinzl M, Wyndaele JJ. Visceral pain is the most debilitating symptom of painful bladder syndrome. *Eur. Urol.* 2008; 53:60–67. [PubMed: 17900797]
- Schrepf A, O'Donnell M, Luo Y, Bradley CS, Kreder K, Lutgendorf S. Inflammation and inflammatory control in interstitial cystitis/bladder pain syndrome: Associations with painful symptoms. Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network. *Pain.* 2014 (Epub ahead of print).
- Rudick CN, Pavlov VI, Chen MC, Klumpp DJ. Gender specific pelvic pain severity in neurogenic cystitis. *J. Urol.* 2012; 187:715–724. [PubMed: 22177208]
- Alvarez-Jaimes LJ, Palmer JA. The role of endocannabinoids in pain modulation and the therapeutic potential of inhibiting their enzymatic degradation. *Curr Pharm Biotechnol.* 2011; 12:1644–1659. [PubMed: 21466449]
- Schlosburg JE, Kinsey SG, Lichtman AH AH. Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation. *AAPS. J.* 2009; 11:39–44. [PubMed: 19184452]
- Blankman JL, Cravatt BF BF. Chemical probes of endocannabinoid metabolism. *Pharmacol.* 2013; 65:849–871.
- Merriam FV, Wang ZY, Hillard CJ, Stuhr KL, Bjorling DE. Inhibition of fatty acid amide hydrolase suppresses referred hyperalgesia induced by bladder inflammation. *BJU Int.* 2011; 108:1145–1149. [PubMed: 20804480]
- Wang ZY, Wang P, Hillard CJ, Bjorling DE. Attenuation of Cystitis and Pain Sensation in Mice Lacking Fatty Acid Amide Hydrolase. *J. Mol. Neurosci.* 2014 in press.
- Aizawa N, Hedlund P, Füllhase C, Ito H, Homma Y, Igawa Y. Inhibition of Peripheral FAAH Depresses Activities of Bladder Mechanosensitive Nerve Fibers of the Rat. *J. Urol.* 2014 [Epub ahead of print].
- Walczak JS, Cervero F. Local activation of cannabinoid CB₁ receptors in the urinary bladder reduces the inflammation-induced sensitization of bladder afferents. *Mol. Pain.* 2011; 7:31. [PubMed: 21554718]
- McKelvey L, Shorten GD, O'Keefe GW. Nerve growth factor-mediated regulation of pain signalling and proposed new intervention strategies in clinical pain management. *J. Neurochem.* 2013; 124:276–289. [PubMed: 23157347]
- Vizzard MA. Changes in urinary bladder neurotrophic factor mRNA and NGF protein following urinary bladder dysfunction. *Exp. Neurol.* 2000; 161:273–284. [PubMed: 10683293]
- Lamb K, Gebhart GF, Bielefeldt K. Increased nerve growth factor expression triggers bladder overactivity. *J. Pain.* 2004; 5:150–156. [PubMed: 15106127]
- Ochodnick P, Cruz CD, Yoshimura N, Cruz F. Neurotrophins as regulators of urinary bladder function. *Nat. Rev. Urol.* 2012; 9:628–637. [PubMed: 23045265]
- Farquhar-Smith WP, Jaggar SI, Rice AS. Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors. *Pain.* 2002; 97:11–21. [PubMed: 12031775]
- Chuang YC, Fraser MO, Yu Y, Chancellor MB, de Groat WC, Yoshimura N. The role of bladder afferent pathways in bladder hyperactivity induced by the intravesical administration of nerve growth factor. *J. Urol.* 2011; 165:975–979. [PubMed: 11176525]
- Guerios SD, Wang ZY, Bjorling DE. Nerve growth factor mediates peripheral mechanical hypersensitivity that accompanies experimental cystitis in mice. *Neurosci. Lett.* 2006; 392:193–197. [PubMed: 16203088]
- Coelho A, Wolf-Johnston AS, Shinde S, Cruz CD, Cruz F, Avelino A, Birder LA. Urinary bladder inflammation induces changes in urothelial nerve growth factor and vanilloid receptor 1. *Br. J. Pharmacol.* 2014 [Epub ahead of print].
- Schnegelsberg B, Sun TT, Cain G, Bhattacharya A, Nunn PA, Ford AP, Vizzard MA, Cockayne DA. Overexpression of NGF in mouse urothelium leads to neuronal hyperinnervation, pelvic

- sensitivity, and changes in urinary bladder function. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 2010; 298:R534–547. [PubMed: 20032263]
20. Zvara P, Vizzard MA. Exogenous overexpression of nerve growth factor in the urinary bladder produces bladder overactivity and altered micturition circuitry in the lumbosacral spinal cord. *BMC Physiol.* 2007; 7:9. [PubMed: 17725832]
 21. Frias B, Charrua A, Avelino A, Michel MC, Cruz F, Cruz CD. Transient receptor potential vanilloid 1 mediates nerve growth factor-induced bladder hyperactivity and noxious input. *BJU Int.* 2012; 110:E422–428. [PubMed: 22540670]
 22. Wang ZY, McDowell T, Wang P, Alvarez R, Gomez T, Bjorling DE. Activation of CB1 inhibits NGF-induced sensitization of TRPV1 in adult mouse afferent neurons. *Neuroscience.* 2014; 277:679–689. [PubMed: 25088915]
 23. Hong S, Zheng G, Wu X, Snider NT, Owyang C, Wiley JW. Corticosterone mediates reciprocal changes in CB 1 and TRPV1 receptors in primary sensory neurons in the chronically stressed rat. *Gastroenterology.* 2011; 140:627–637. [PubMed: 21070780]
 24. Khasabova IA, Harding-Rose C, Simone DA, Seybold VS. Differential effects of CB1 and opioid agonists on two populations of adult rat dorsal root ganglion neurons. *J. Neurosci.* 2004; 24:1744–1753. [PubMed: 14973253]
 25. Agarwal N, Pacher P, Tegeder I, Amaya F, Constantin CE, Brenner GJ, Rubino T, Michalski CW, Marsicano G, Monory K, Mackie K, Marian C, Batkai S, Parolaro D, Fischer MJ, Reeh P, Kunos G, Kress M, Lutz B, Woolf CJ, Kuner R. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. *Nat. Neurosci.* 2007; 10:870–879. [PubMed: 17558404]
 26. Veress G, Meszar Z, Muszil D, Avelino A, Matesz K, Mackie K, Nagy I. Characterisation of cannabinoid 1 receptor expression in the perikarya, and peripheral and spinal processes of primary sensory neurons. *Brain Struct. Funct.* 2013; 218:733–750. [PubMed: 22618437]
 27. Averill S, McMahon SB, Clary DO, Reichardt LF, Priestley JV. Immunocytochemical localization of trkA receptors in chemically identified subgroups of adult rat sensory neurons. *Eur. J. Neurosci.* 1995; 7:1484–1494. [PubMed: 7551174]
 28. Walczak JS, Price TJ, Cervero F. Cannabinoid CB1 receptors are expressed in the mouse urinary bladder and their activation modulates afferent bladder activity. *Neuroscience.* 2009; 159:1154–1163. [PubMed: 19356696]
 29. Dinh QT, Groneberg DA, Peiser C, Mingomataj E, Joachim RA, Witt C, Arck PC, Klapp BF, Fischer A. Substance P expression in TRPV1 and trkA-positive dorsal root ganglion neurons innervating the mouse lung. *Respir. Physiol. Neurobiol.* 2004; 144:15–24. [PubMed: 15522699]
 30. Qiao LY, Yu SJ, Kay JC, Xia CM. In vivo regulation of brain-derived neurotrophic factor in dorsal root ganglia is mediated by nerve growth factor-triggered Akt activation during cystitis. *PLoS One.* 2013; 8:e81547. [PubMed: 24303055]
 31. Murray E, Malley SE, Qiao LY, Hu VY, Vizzard MA. Cyclophosphamide induced cystitis alters neurotrophin and receptor tyrosine kinase expression in pelvic ganglia and bladder. *J. Urol.* 2004; 172:2434–2439. [PubMed: 15538286]
 32. Hedlund P. Cannabinoids and the endocannabinoid system in lower urinary tract function and dysfunction. *Neurourol. Urodyn.* 2014; 33:46–53.
 33. Farquhar-Smith WP, Rice AS. A novel neuroimmune mechanism in cannabinoid-mediated attenuation of nerve growth factor-induced hyperalgesia. *Anesthesiology.* 2003; 99:1391–1401. [PubMed: 14639155]
 34. Bakali E, Elliott RA, Taylor AH, Willets J, Konje JC, Tincello DG. Distribution and function of the endocannabinoid system in the rat and human bladder. *Int. Urogynecol J.* 2013; 24:855–863. [PubMed: 23081739]
 35. Tyagi V, Philips BJ, Su R, Smaldone MC, Erickson VL, Chancellor MB, Yoshimura N, Tyagi P. Differential expression of functional cannabinoid receptors in human bladder detrusor and urothelium. *J. Urol.* 2009; 181:1932–1938. [PubMed: 19237176]
 36. Birder L, Andersson KE. Urothelial signaling. *Physiol. Rev.* 2013; 93:653–680. [PubMed: 23589830]

37. Hill WG. Control of Urinary Drainage and Voiding. *Clin. J. Am. Soc. Nephrol.* 2014 (Epub ahead of print).
38. Keay SK, Birder LA, Chai TC. Evidence for bladder urothelial pathophysiology in functional bladder disorders. *Biomed. Res. Int.* 2014;865463. [PubMed: 24900993]
39. Merriam FV, Wang ZY, Guerios SD, Bjorling DE. Cannabinoid receptor 2 is increased in acutely and chronically inflamed bladder of rats. *Neurosci. Lett.* 445(2008):130–134. [PubMed: 18778751]
40. Gandaglia G, Strittmatter F, La Croce G, Benigni F, Bettiga A, Castiglione F, Moschini M, Mistretta F, Gratzke C, Montorsi F, Stief C, Hedlund P. The fatty acid amide hydrolase inhibitor oleoyl ethyl amide counteracts bladder overactivity in female rats. *Neurourol. Urodyn.* 2014; 33:1251–1258. [PubMed: 24038381]

Figure 1.

Representative photoimages showing localization of CB1 and trkA in adult mouse L6 DRG neurons (arrow heads) and nerve fibers (arrows) in both WT and FAAH KO mice. Neurons were considered labeled with the specific antibody when the fluorescent intensity was distinctively higher than background. Specific staining of CB1 and trkA was also observed in urothelium (arrow heads) and nerve fibers (arrows) in bladders of both genotypes. Using IgG from normal, non-immunized rabbit (instead of specific antibodies) resulted in complete

lack of specific staining (not shown). U: urothelium. L: bladder lumen. Scale bar indicates 100 μm .

Figure 2.

A: Representative tracings showing that infusion of saline into bladder induced micturition contraction following the treatments. B: Intravesical NGF reduced the amount of saline needed to induce maximal micturition pressure. Treatment with ACEA prevented stimulatory effects of NGF and inhibitory effects of ACEA were reversed by the selective CB1 antagonist AM251. C: Treatment with NGF, ACEA+NGF, or AM251+ACEA+NGF did not affect maximal micturition pressure. Data were analyzed using one-way ANOVA followed by post hoc Tukey's multiple comparison test. $n = 6-8$ in each group. * $p < 0.05$ vs vehicle-treated. # $p < 0.05$ vs NGF-treated.

Fig. 3.

A: Treatment with NGF did not alter the amount of saline needed to induce maximal micturition pressure in FAAH KO mice, but treatment with the selective CB1 antagonist AM251 prior to NGF significantly reduced the amount of saline needed to induce maximal micturition pressure. B: Treatment with NGF or AM251 +NGF did not affect maximal micturition pressure. Data were analyzed using one-way ANOVA followed by post hoc Tukey's multiple comparison test. $n = 6-8$ in each group. ** $p < 0.01$ vs NGF-treated.